Evidence that host size determines liver size: Studies in dogs receiving orthotopic liver transplants

Igal Kam, Steven Lynch, Gregory Svanas, Satori Todo, Lorenzo Polimeno, Antonio Francavilla, Ronald J. Penkrot, Sunichi Takaya, Bo G. Ericzon, Thomas E. Starzl, David H. Van Thiel – 1 March 1987 – Orthotopic liver transplantation was performed in two groups of dogs; Group I animals consisted of large dogs that served as recipients of livers obtained from smaller dogs while Group II animals consisted of dogs that received liver from donor dogs of nearly the same size.

Cytophotometric measurements of nuclear DNA content in hepatocellular carcinomas

Sow‐Hsong Kuo, Jin‐Chuan Sheu, Ding‐Shinn Chen, Juei‐Low Sung, Chi‐Chung Lin, Hey‐Chi Hsu – 1 March 1987 – The nuclear DNA contents of 54 hepatocellular carcinomas were measured on cytologic smears using a scanning microdensitometer at a wavelength of 550 nm. The cellular materials were aspirated under ultrasonographic guidance and stained with modified Feulgen method. The DNA modal values, which could be defined in 51 cases, ranged from 2.2 to 9.8 ploidy, with 46.3% (25/54) in hypertetraploidy.

Accumulation of 7α‐hydroxy‐4‐cholesten‐3‐one and cholesta‐4,6‐dien‐3‐one in patients with cerebrotendinous xanthomatosis: Effect of treatment with chenodeoxycholic acid

Ingemar Björkhem, Sverre Skrede, Marie S. Buchmann, Cara East, Scott Grundy – 1 March 1987 – Evidence was recently presented that an essential part of the accumulation of cholestanol in patients with cerebrotendinous xanthomatosis is due to acceleration of a novel pathway, involving 7α‐hydroxylated intermediates in bile acid biosynthesis as precursors (J. Clin. Invest. 1985; 75:448–456). Such intermediates accumulate in patients with cerebrotendinous xanthomatosis due to lack of the mitochondrial 26‐hydroxylase involved in the major pathway for bile acid biosynthesis.

The diagnosis of hepatic metastases: Converting a chance into a choice

Klemens B. Meyer, Jerome P. Kassirer – 1 March 1987 – Clinicians frequently perform tests to determine whether patients have liver metastases. Optimal use of a laboratory test requires that the clinician know the test's operating characteristics (its sensitivity and specificity) and have an estimate of the pretest probability that disease is present. We have surveyed studies that examined the value of four biochemical and three imaging tests in establishing a diagnosis of hepatic metastases in patients who underwent an invasive procedure to establish the presence or absence of disease.

Encapsulated hepatocellular carcinoma in the absence of cirrhosis: A favorable prognosis

Fenton Schaffner – 1 March 1987 – Clinicopathological features were studied in 41 patients with histology‐proven hepatocellular carcinoma without cirrhosis. Of these, 13 (31.7%) were positive for hepatitis B virus surface antigen (HBsAg) and 28 were negative. Twenty‐six of 28 (92.9%) HBsAg negative cases had anticore antibody (anti‐HBc) of low titres. The age of patients at the time of diagnosis of hepatocellular carcinoma was significantly younger in the HBsAg positive cases compared with the negative.

Le Veen vs. Denver peritoneovenous shunts: Inadequate numbers or technique?

Laurence M. Blendis, Robert H. Lund – 1 March 1987 – Peritoneovenous shunts (PVSs) have provided salutary effects on medically recalcitrant ascites, functional renal impairment, nutritional derangements, ventilatory embarrassment, and locomotion potential in patients with cirrhosis. While the LeVeen (LPVS) and Denver (DPVS) PVSs are most frequently implanted in such patients, postoperative complications of bleeding gastroesophageal varices, sepsis, and shunt occlusion occur with notable frequency.

Subscribe to